Literature DB >> 10516022

Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

G S Ogg1, S Kostense, M R Klein, S Jurriaans, D Hamann, A J McMichael, F Miedema.   

Abstract

Few studies have examined longitudinal changes in human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocytes (CTL). To more closely define the natural history of HIV-specific CTL, we used HLA-peptide tetrameric complexes to study the longitudinal CD8(+) T-cell response evolution in 16 A*0201-positive untreated individuals followed clinically for up to 14 years. As early as 1 to 2 years after seroconversion, we found a significant association between high frequencies of A*0201-restricted p17(Gag/Pol) tetramer-binding cells and slower disease progression (P < 0.01). We observed that responses could remain stable over many months, but any longitudinal changes that occurred were typically accompanied by reciprocal changes in RNA viral load. Phenotypic analysis with markers CD45RO, CD45RA, and CD27 identified distinct subsets of antigen-specific cells and the preferential loss of CD27(+) CD45RO(+) cells during periods of rapid decline in the frequency of tetramer-binding cells. In addition we were unable to confirm previous studies showing a consistent selective loss of HIV-specific cells in the context of sustained Epstein-Barr virus-specific cell frequencies. Overall, these data support a role of HIV-specific CTL in the control of disease progression and suggest that the ultimate loss of such CTL may be preferentially from the CD27(+) CD45RO(+) subset.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516022      PMCID: PMC112948     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Human immunodeficiency virus type 1 (HIV-1)--and Epstein-Barr virus--specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1--infected persons.

Authors:  A M Geretti; M E Dings; C A van Els; C A van Baalen; F J Wijnholds; J C Borleffs; A D Osterhaus
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

2.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.

Authors:  T C Greenough; D B Brettler; M Somasundaran; D L Panicali; J L Sullivan
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

3.  In vivo estimates of division and death rates of human T lymphocytes.

Authors:  A R Mclean; C A Michie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

4.  Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.

Authors:  T Harrer; E Harrer; S A Kalams; T Elbeik; S I Staprans; M B Feinberg; Y Cao; D D Ho; T Yilma; A M Caliendo; R P Johnson; S P Buchbinder; B D Walker
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-01       Impact factor: 2.205

5.  Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma.

Authors:  M J Kersten; M R Klein; A M Holwerda; F Miedema; M H van Oers
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.

Authors:  P A Moss; S L Rowland-Jones; P M Frodsham; S McAdam; P Giangrande; A J McMichael; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

7.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

8.  Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.

Authors:  Y Rivière; M B McChesney; F Porrot; F Tanneau-Salvadori; P Sansonetti; O Lopez; G Pialoux; V Feuillie; M Mollereau; S Chamaret
Journal:  AIDS Res Hum Retroviruses       Date:  1995-08       Impact factor: 2.205

9.  Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.

Authors:  N M Steven; N E Annels; A Kumar; A M Leese; M G Kurilla; A B Rickinson
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

10.  Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

Authors:  P J Goulder; A K Sewell; D G Lalloo; D A Price; J A Whelan; J Evans; G P Taylor; G Luzzi; P Giangrande; R E Phillips; A J McMichael
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

View more
  46 in total

1.  Ex vivo analysis of phenotype and TCR usage in relation to CD45 isoform expression on cytomegalovirus-specific CD8+ T lymphocytes.

Authors:  A L Vargas; F Lechner; M Kantzanou; R E Phillips; P Klenerman
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  Immune response and virus population composition: HIV as a case study.

Authors:  Gal Almogy; Netta Cohen; Sabine Stöcker; Lewi Stone
Journal:  Proc Biol Sci       Date:  2002-04-22       Impact factor: 5.349

3.  A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Authors:  P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy.

Authors:  Michael P Weekes; Mark R Wills; J G Patrick Sissons; Andrew J Carmichael
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

5.  Impact of immune plasticity on development of cellular memory responses to human immunodeficiency virus type 1.

Authors:  Michael A Kolber
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

6.  Impact of opportunistic Mycobacterium tuberculosis infection on the phenotype of peripheral blood T cells of AIDS patients.

Authors:  Germán Bernal-Fernández; Carlos Hermida; Patricia Espinosa-Cueto; Ana Cristina Cubilla-Tejeda; Jesús Fidel Salazar-González; Librado Ortiz-Ortiz; Rosario Leyva-Meza; Hugo Diaz-Silvestre; Raul Mancilla
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

7.  Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals.

Authors:  Sanjay Mendiratta; Madhu Vajpayee; Uma Malhotra; Shweta Kaushik; Lalit Dar; Kamalika Mojumdar; Neeraj Kumar Chauhan; Vishnubhatla Sreenivas
Journal:  Med Microbiol Immunol       Date:  2008-11-05       Impact factor: 3.402

8.  A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.

Authors:  Theresa Li-Yun Chang; Arevik Mosoian; Richard Pine; Mary E Klotman; John P Moore
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

9.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.